Biohaven is seeking to reverse the fate of its embattled experimental drug troriluzole in spinocerebellar ataxia — a ...

UCB’s Bimzelx scored three more FDA approvals on Monday, making it the first and only IL-17A and IL-17F inhibitor approved in ...

For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and ...

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...

Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

Plus, news about Longevity Biomedical, Sensorion, Teva and Bristol Myers Squibb: Context Therapeutics buys a T cell engager: The biotech will pay $15 million upfront and up to $118.5 million in ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...